PolyNovo Says US PMA Submission for NovoSorb BTM Now Expected Before 2026-End; Shares Down 4%

MT Newswires Live05-29

PolyNovo (ASX:PNV) said the clinical study report for its US pivotal randomized controlled trial of NovoSorb BTM has been finalized, with the premarket approval (PMA) submission now expected before the end of calendar 2026, according to a Friday Australian bourse filing.

NovoSorb, the company's polymer, is made to address unmet needs in wound care, as evidenced by its clinical adoption and patient outcomes, and the company is leveraging the technology platform to develop new products and markets, the filing said.

The company said it has proactively refined its PMA submission plan following updated Food and Drug Administration (FDA) guidance effective from February, including the sequencing of key manufacturing and validation activities, with certain activities originally planned post-submission to be included to strengthen the submission package.

The revised timing does not impact current sales or clinical use of NovoSorb products, the filing added.

The company's shares fell 4% in recent Friday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2639064597?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 11:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2639064597","market":"hk","top_or_hot":-1,"title":"PolyNovo Says US PMA Submission for NovoSorb BTM Now Expected Before 2026-End; Shares Down 4%","media":"MT Newswires Live","content":"<html><body><p> PolyNovo (ASX:PNV) said the clinical study report for its US pivotal randomized controlled trial of NovoSorb BTM has been finalized, with the premarket approval (PMA) submission now expected before the end of calendar 2026, according to a Friday Australian bourse filing.</p><p>NovoSorb, the company's polymer, is made to address unmet needs in wound care, as evidenced by its clinical adoption and patient outcomes, and the company is leveraging the technology platform to develop new products and markets, the filing said.</p><p>The company said it has proactively refined its PMA submission plan following updated Food and Drug Administration (FDA) guidance effective from February, including the sequencing of key manufacturing and validation activities, with certain activities originally planned post-submission to be included to strengthen the submission package.</p><p>The revised timing does not impact current sales or clinical use of NovoSorb products, the filing added.</p><p>The company's shares fell 4% in recent Friday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PolyNovo Says US PMA Submission for NovoSorb BTM Now Expected Before 2026-End; Shares Down 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPolyNovo Says US PMA Submission for NovoSorb BTM Now Expected Before 2026-End; Shares Down 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-29 11:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> PolyNovo (ASX:PNV) said the clinical study report for its US pivotal randomized controlled trial of NovoSorb BTM has been finalized, with the premarket approval (PMA) submission now expected before the end of calendar 2026, according to a Friday Australian bourse filing.</p><p>NovoSorb, the company's polymer, is made to address unmet needs in wound care, as evidenced by its clinical adoption and patient outcomes, and the company is leveraging the technology platform to develop new products and markets, the filing said.</p><p>The company said it has proactively refined its PMA submission plan following updated Food and Drug Administration (FDA) guidance effective from February, including the sequencing of key manufacturing and validation activities, with certain activities originally planned post-submission to be included to strengthen the submission package.</p><p>The revised timing does not impact current sales or clinical use of NovoSorb products, the filing added.</p><p>The company's shares fell 4% in recent Friday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PNV.AU","symbol_name":"POLYNOVO LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2639064597","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2639064597","pubTimestamp":1780025260,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PolyNovo  said the clinical study report for its US pivotal randomized controlled trial of NovoSorb BTM has been finalized, with the premarket approval  submission now expected before the end of calendar 2026, according to a Friday Australian bourse filing.NovoSorb, the company's polymer, is made to address unmet needs in wound care, as evidenced by its clinical adoption and patient outcomes, and the company is leveraging the technology platform to develop new products and markets, the filing said.The company said it has proactively refined its PMA submission plan following updated Food and Drug Administration  guidance effective from February, including the sequencing of key manufacturing and validation activities, with certain activities originally planned post-submission to be included to strengthen the submission package.The revised timing does not impact current sales or clinical use of NovoSorb products, the filing added.The company's shares fell 4% in recent Friday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PNV.AU":"POLYNOVO LTD","BK7508":"医药生物股","BK4137":"综合支持服务","BK7126":"医疗保健用品","BTM":"Bitcoin Depot Inc."},"translate_title":"PolyNovo表示，NovoSorb BTM目前预计将于2026年底前提交美国PMA；股价下跌4%","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PNV.AU":1,"BTM":1.5},"content_text":"PolyNovo (ASX:PNV) said the clinical study report for its US pivotal randomized controlled trial of NovoSorb BTM has been finalized, with the premarket approval (PMA) submission now expected before the end of calendar 2026, according to a Friday Australian bourse filing.NovoSorb, the company's polymer, is made to address unmet needs in wound care, as evidenced by its clinical adoption and patient outcomes, and the company is leveraging the technology platform to develop new products and markets, the filing said.The company said it has proactively refined its PMA submission plan following updated Food and Drug Administration (FDA) guidance effective from February, including the sequencing of key manufacturing and validation activities, with certain activities originally planned post-submission to be included to strengthen the submission package.The revised timing does not impact current sales or clinical use of NovoSorb products, the filing added.The company's shares fell 4% in recent Friday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2639064597","isCrawlerRequest":true}